Tags

Type your tag names separated by a space and hit enter

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.
Nature. 2021 05; 593(7857):136-141.Nat

Abstract

Transmission of SARS-CoV-2 is uncontrolled in many parts of the world; control is compounded in some areas by the higher transmission potential of the B.1.1.7 variant1, which has now been reported in 94 countries. It is unclear whether the response of the virus to vaccines against SARS-CoV-2 on the basis of the prototypic strain will be affected by the mutations found in B.1.1.7. Here we assess the immune responses of individuals after vaccination with the mRNA-based vaccine BNT162b22. We measured neutralizing antibody responses after the first and second immunizations using pseudoviruses that expressed the wild-type spike protein or a mutated spike protein that contained the eight amino acid changes found in the B.1.1.7 variant. The sera from individuals who received the vaccine exhibited a broad range of neutralizing titres against the wild-type pseudoviruses that were modestly reduced against the B.1.1.7 variant. This reduction was also evident in sera from some patients who had recovered from COVID-19. Decreased neutralization of the B.1.1.7 variant was also observed for monoclonal antibodies that target the N-terminal domain (9 out of 10) and the receptor-binding motif (5 out of 31), but not for monoclonal antibodies that recognize the receptor-binding domain that bind outside the receptor-binding motif. Introduction of the mutation that encodes the E484K substitution in the B.1.1.7 background to reflect a newly emerged variant of concern (VOC 202102/02) led to a more-substantial loss of neutralizing activity by vaccine-elicited antibodies and monoclonal antibodies (19 out of 31) compared with the loss of neutralizing activity conferred by the mutations in B.1.1.7 alone. The emergence of the E484K substitution in a B.1.1.7 background represents a threat to the efficacy of the BNT162b2 vaccine.

Authors+Show Affiliations

Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK. Department of Medicine, University of Cambridge, Cambridge, UK. Division of Infection and Immunity, University College London, London, UK.Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK. Department of Medicine, University of Cambridge, Cambridge, UK.Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK. Department of Medicine, University of Cambridge, Cambridge, UK.Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK. Department of Medicine, University of Cambridge, Cambridge, UK. Division of Infection and Immunity, University College London, London, UK.Department of Biochemistry, University of Washington, Seattle, WA, USA.Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK. Department of Medicine, University of Cambridge, Cambridge, UK. Division of Infection and Immunity, University College London, London, UK.Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.Department of Biochemistry, University of Washington, Seattle, WA, USA.Department of Biochemistry, University of Washington, Seattle, WA, USA.Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.Vir Biotechnology, San Francisco, CA, USA.Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, Lugano, Switzerland.Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, Lugano, Switzerland.Division of Infectious Diseases, Luigi Sacco Hospital, University of Milan, Milan, Italy.No affiliation info availableNIHR Cambridge Clinical Research Facility, Cambridge, UK.NIHR Bioresource, Cambridge, UK.NIHR Bioresource, Cambridge, UK.Division of Infection and Immunity, University College London, London, UK.Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK. Department of Medicine, University of Cambridge, Cambridge, UK.Department of Medicine, University of Cambridge, Cambridge, UK. NIHR Bioresource, Cambridge, UK.University of Kent, Canturbury, UK.Department of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge, UK.Department of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge, UK. Laboratorio de Inmunologia, UNAM, Cuautitlán, Mexico.No affiliation info availableInstitute of Biodiversity, University of Glasgow, Glasgow, UK.Vir Biotechnology, San Francisco, CA, USA.Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.Department of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge, UK. Department of Haematology, University of Cambridge, Cambridge, UK.Department of Medicine, University of Cambridge, Cambridge, UK.Department of Biochemistry, University of Washington, Seattle, WA, USA.Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. dcorti@vir.bio.Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK. rkg20@cam.ac.uk. Department of Medicine, University of Cambridge, Cambridge, UK. rkg20@cam.ac.uk. Department of Haematology, University of Cambridge, Cambridge, UK. rkg20@cam.ac.uk. University of KwaZulu Natal, Durban, South Africa. rkg20@cam.ac.uk. Africa Health Research Institute, Durban, South Africa. rkg20@cam.ac.uk. Department of Infectious Diseases, Cambridge University Hospitals NHS Trust, Cambridge, UK. rkg20@cam.ac.uk.

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

33706364

Citation

Collier, Dami A., et al. "Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA Vaccine-elicited Antibodies." Nature, vol. 593, no. 7857, 2021, pp. 136-141.
Collier DA, De Marco A, Ferreira IATM, et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature. 2021;593(7857):136-141.
Collier, D. A., De Marco, A., Ferreira, I. A. T. M., Meng, B., Datir, R. P., Walls, A. C., Kemp, S. A., Bassi, J., Pinto, D., Silacci-Fregni, C., Bianchi, S., Tortorici, M. A., Bowen, J., Culap, K., Jaconi, S., Cameroni, E., Snell, G., Pizzuto, M. S., Pellanda, A. F., ... Gupta, R. K. (2021). Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature, 593(7857), 136-141. https://doi.org/10.1038/s41586-021-03412-7
Collier DA, et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA Vaccine-elicited Antibodies. Nature. 2021;593(7857):136-141. PubMed PMID: 33706364.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. AU - Collier,Dami A, AU - De Marco,Anna, AU - Ferreira,Isabella A T M, AU - Meng,Bo, AU - Datir,Rawlings P, AU - Walls,Alexandra C, AU - Kemp,Steven A, AU - Bassi,Jessica, AU - Pinto,Dora, AU - Silacci-Fregni,Chiara, AU - Bianchi,Siro, AU - Tortorici,M Alejandra, AU - Bowen,John, AU - Culap,Katja, AU - Jaconi,Stefano, AU - Cameroni,Elisabetta, AU - Snell,Gyorgy, AU - Pizzuto,Matteo S, AU - Pellanda,Alessandra Franzetti, AU - Garzoni,Christian, AU - Riva,Agostino, AU - ,, AU - Elmer,Anne, AU - Kingston,Nathalie, AU - Graves,Barbara, AU - McCoy,Laura E, AU - Smith,Kenneth G C, AU - Bradley,John R, AU - Temperton,Nigel, AU - Ceron-Gutierrez,Lourdes, AU - Barcenas-Morales,Gabriela, AU - ,, AU - Harvey,William, AU - Virgin,Herbert W, AU - Lanzavecchia,Antonio, AU - Piccoli,Luca, AU - Doffinger,Rainer, AU - Wills,Mark, AU - Veesler,David, AU - Corti,Davide, AU - Gupta,Ravindra K, Y1 - 2021/03/11/ PY - 2021/01/26/received PY - 2021/03/01/accepted PY - 2021/3/12/pubmed PY - 2021/5/12/medline PY - 2021/3/11/entrez SP - 136 EP - 141 JF - Nature JO - Nature VL - 593 IS - 7857 N2 - Transmission of SARS-CoV-2 is uncontrolled in many parts of the world; control is compounded in some areas by the higher transmission potential of the B.1.1.7 variant1, which has now been reported in 94 countries. It is unclear whether the response of the virus to vaccines against SARS-CoV-2 on the basis of the prototypic strain will be affected by the mutations found in B.1.1.7. Here we assess the immune responses of individuals after vaccination with the mRNA-based vaccine BNT162b22. We measured neutralizing antibody responses after the first and second immunizations using pseudoviruses that expressed the wild-type spike protein or a mutated spike protein that contained the eight amino acid changes found in the B.1.1.7 variant. The sera from individuals who received the vaccine exhibited a broad range of neutralizing titres against the wild-type pseudoviruses that were modestly reduced against the B.1.1.7 variant. This reduction was also evident in sera from some patients who had recovered from COVID-19. Decreased neutralization of the B.1.1.7 variant was also observed for monoclonal antibodies that target the N-terminal domain (9 out of 10) and the receptor-binding motif (5 out of 31), but not for monoclonal antibodies that recognize the receptor-binding domain that bind outside the receptor-binding motif. Introduction of the mutation that encodes the E484K substitution in the B.1.1.7 background to reflect a newly emerged variant of concern (VOC 202102/02) led to a more-substantial loss of neutralizing activity by vaccine-elicited antibodies and monoclonal antibodies (19 out of 31) compared with the loss of neutralizing activity conferred by the mutations in B.1.1.7 alone. The emergence of the E484K substitution in a B.1.1.7 background represents a threat to the efficacy of the BNT162b2 vaccine. SN - 1476-4687 UR - https://www.unboundmedicine.com/medline/citation/33706364/Sensitivity_of_SARS_CoV_2_B_1_1_7_to_mRNA_vaccine_elicited_antibodies_ L2 - https://doi.org/10.1038/s41586-021-03412-7 DB - PRIME DP - Unbound Medicine ER -